July 1, 2019 8:14am

Accordingly the sector, “our” universe will share in the spoils of the upside trend

News: Alnylam Pharmaceuticals (ALNY) submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).

Pre-open Indications: pricing attained will not always be value perceived

As the first session of July week – a short one interspersed with a holiday, volatility and momentum will be the key determinants as Q3 begins

 

The 6 W’s: Who, what, where, when, why and what of it … the real question is who is going to do what?

 

Dow futures are UP +0.97% (+257 points), S&P futures are UP +1.12% (+33 points) and also are NASDAQ futures UP +1.79% (+138 points)

 

U.S. stock futures surged on Monday morning after the U.S. and China agreed to hold off on slapping additional tariffs on their products in an effort to resume trade talks;

European stocks traded higher with the pan-European Stoxx 600 jumped was up 0.9% late morning, slightly down from its opening highs after weak euro zone PMI data;

Asia Pacific markets rose however data released (Monday) from a private survey showed that Chinese factory activity in June shrank unexpectedly.

 

Data docket: ISM manufacturing and construction spending data are expected at 10 a.m. ET.

 

Henry’omics:

Markets appear to be poised with the cooperative tone coming out of U.S. and China meetings.

The week’s pricing trend will be spread-out as the holiday falls on Thursday with many splitting early for a long weekend!

GO with the FLOW!

As I had stated on Friday night’s close, “Stocks are NOT that pricey but, when they burst higher; there is always a downside reaction as many holders prepare for LPS (loss-per-share) earnings reporting.”

 

From Friday night’s post, “it’s over … Friday’s session, last week, June, Q2 and the first half. Volume increased to the upside, though risk has its vicissitudes. Q2 was an example of volatility by headlines and sentiment”

  • The NASDAQ was up +38.49 points or +0.48% to 8,006.24;
  • The close was positive with an A/DL of 33/9 and 0 flat and 2 acquired;
  • The range of the 33 upside was +0.20% (ONCE) to +19.41% (ONVO +$0.085) while the 9 downside ranged from -0.65% (IONS) to -14.57% (BLCM);
  • 16 out of the 33 upside had higher than the 3 month average volume;
  • 7 out of the 9 downside had higher than the 3 month average volume;
    The iShares NASDAQ Biotechnology (IBB) indicator: Friday closed up +1.70% after Thursday’s closed +1.38%, Wednesday -1%, Tuesday’s -0.21% and  last Monday closing down -2.13%.

 

Q2/19:

  • In June, there were 9 positive, 1 neutral and 10 negative closes;
  • In May, there were 14 negative, 1 holiday and 8 positive closes;
  • In April, there has been 10 positive and 11 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context: post earnings release:

  • There are many OVERSOLD but, a holiday interruptus exists

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.